New Drug Pathway Must Weigh Risk, Off-Label Use, FDA Hears
A U.S. Food and Drug Administration panel Monday weighed competing visions of a proposed approval pathway for pharmaceuticals targeting unmet medical needs, with advocates for drugmakers, doctors and patients debating appropriate...To view the full article, register now.
Already a subscriber? Click here to view full article